From: Update of the Preventive Antibiotics in Stroke Study (PASS): statistical analysis plan
Baseline characteristics | Ceftriaxone + standard care | Standard care |
---|---|---|
Age - years | Â | Â |
Male sex - % n/N | Â | Â |
Medical history - % n/N | Â | Â |
- Atrial fibrillation/flutter | Â | Â |
- Stroke | Â | Â |
- Hypercholesterolemia | Â | Â |
- Hypertension | Â | Â |
- Myocardial infarction | Â | Â |
- Cardiac valve insufficiency/stenosis/replacement | Â | Â |
- Peripheral vascular disease | Â | Â |
- Obstructive pulmonary disease | Â | Â |
- Immunocompromised | Â | Â |
Current smoker - % n/N | Â | Â |
Medication prior to stroke - % n/N | Â | Â |
- Anticoagulants | Â | Â |
- Antiplatelet | Â | Â |
- Statin | Â | Â |
- ACE inhibitor | Â | Â |
- Bèta-blocker |  |  |
- Proton pump inhibitor | Â | Â |
Disability prior to stroke - mRS * | Â | Â |
Stroke severity - NIHSS ** | Â | Â |
Swallowing screening performed - % n/N | Â | Â |
Dysphagic patients - % n/N | Â | Â |
Acute treatment - % n/N | Â | Â |
- IV thrombolysis | Â | Â |
- Coagulant therapy | Â | Â |
Diagnosis at discharge - % n/N | Â | Â |
- Infarction | Â | Â |
- Hemorrhage | Â | Â |
- Transient ischemic attack (TIA) | Â | Â |
- Other | Â | Â |